GLP-1 vs bariatric surgery statistics in the U.S.

What the weight-loss averages mean

In STEP 1, people without diabetes taking semaglutide 2.4 mg lost an average of 14.9% of starting body weight at week 68, compared with 2.4% with placebo. For a person starting at 250 pounds, 14.9% is about 37 pounds. Results varied from person to person, and the trial result does not guarantee what will happen outside a closely monitored study. In SURMOUNT-1, tirzepatide 15 mg produced an average 20.9% loss at week 72, compared with 3.1% with placebo. At 250 pounds, that average is about 52 pounds. The timeframes are long enough to matter: these are not results expected after a few injections. Surgery often produces larger early average losses. In a PCORnet study of people with type 2 diabetes, average loss at one year was 22.8% after sleeve gastrectomy and 29.1% after Roux-en-Y gastric bypass. At 250 pounds, those averages work out to roughly 57 pounds after sleeve and 73 pounds after bypass, but the study population differs from the medicine trials. Surgery has a larger upfront commitment. It can involve preoperative testing, recovery, permanent anatomy changes, supplements, nutrition laboratory monitoring, and sometimes later procedures. A medicine usually avoids an operation, but it asks a different practical question: can you tolerate it, obtain it, and maintain access over time?

Surgery remains a common option

ASMBS reported 177,297 metabolic and bariatric procedures in the United States for 2024. That was below the 217,387 reported for 2023 and below the newer 2022 series figure of 230,207. The society notes that procedure estimates use evolving methods, so changes across series should be interpreted carefully. Sleeve gastrectomy accounted for 103,452 procedures, or 58.35% of the 2024 total. Roux-en-Y gastric bypass accounted for 58,183 procedures, or 32.82%. Revision procedures made up 10,000 procedures, which matters because some people need further evaluation or treatment after an earlier operation. A falling procedure count does not show that surgery has ceased to matter or that GLP-1 medicines suit every person. Surgery may be considered where a person wants a procedural approach, has health conditions that can benefit, needs a greater average effect, or has not had enough benefit from non-surgical care. Eligibility and coverage are individual matters.

Using a GLP-1 medicine after surgery

Wegovy and Zepbound are approved for chronic weight management in qualifying adults. FDA labeling does not establish a separate approval for weight regain after bariatric surgery. That does not prevent a clinician from considering a medicine when the person's in the full dataset history and approved indication fit, but it means the post-surgery evidence needs careful interpretation. For many people after surgery, the first issue is not simply appetite. A clinician may want to review the operation type, lowest weight after surgery, timing of regain, reflux, vomiting, abdominal pain, eating tolerance, nutrition status, other medicines, sleep, alcohol use, and metabolic conditions. Those details can point toward medication, further testing, nutrition support, revision evaluation, or a combination. In one observational study of liraglutide or semaglutide after bariatric surgery, the median loss was 10.5 kilograms, about 23 pounds, at 12 months. Investigators estimated this represented 99.3% of regained weight. It is an encouraging result, but it cannot promise that result to everyone because people were not randomly assigned and differed in surgery type, time since surgery, medicine exposure, and starting regain. A 2025 systematic review and meta-analysis estimated total weight loss of 9.24% with liraglutide, 11.38% with semaglutide, and 15.50% with tirzepatide after at least three months. These pooled estimates do not establish that tirzepatide is better for every post-surgery patient. They combine observational studies with different populations and follow-up patterns. ClinicalTrials.gov lists NCT06803888, a Cleveland Clinic study comparing bariatric surgery, semaglutide, and tirzepatide. As of the record update posted May 18, 2026, it was active but not recruiting and had no results posted. No direct randomized comparison result is available from that record.

Maintenance and stopping treatment

Starting treatment is only part of the decision. In the STEP 1 extension, people who stopped semaglutide regained an average 11.6 percentage points of body weight over the following year. That was about two-thirds of the weight they had lost during treatment. In SURMOUNT-4, people who continued tirzepatide maintained and added to earlier weight loss, while people switched to placebo regained weight. These studies do not mean every person must make a permanent decision immediately. They do show why it is sensible to discuss insurance renewal, self-pay affordability, side effects, surgery timing, and a backup plan before treatment is interrupted. Surgery also needs maintenance. Weight regain can occur after sleeve gastrectomy and gastric bypass, and it does not by itself mean that someone failed. Long-term follow-up can include nutrition monitoring, supplements, activity and food routines, symptom review, and assessment for anatomical or medical contributors where appropriate.

Cost and coverage questions to ask first

Insurance access can determine the practical choice before clinical preference does. For a GLP-1 medicine, ask whether your plan covers the medicine for your diagnosis, whether prior authorization is required, whether a preferred product must be tried first, what documentation is needed, and when approval must be renewed. Published self-pay offers are not the same as insurance coverage or a guaranteed long-term price. Novo Nordisk lists a $349 monthly offer for certain Wegovy injection doses and $399 for Wegovy HD under stated terms. Lilly lists regular Zepbound self-pay pricing from $299 to $699 per 28-day supply depending on dose and product option, plus a $449 continuing self-pay journey offer for listed higher-dose products with conditions. CMS launched the Medicare GLP-1 Bridge on July 1, 2026. Eligible Medicare Part D beneficiaries may obtain certain GLP-1 medicines for weight loss or weight maintenance for $50 per month through December 31, 2027. It is a limited program rather than universal Medicare obesity-drug coverage, and people already eligible for coverage under their Part D benefit do not qualify through that separate bridge pathway. Bariatric surgery coverage differs by employer plan, marketplace plan, Medicaid program, and Medicare Advantage plan. ASMBS has estimated surgery costs around $17,000 to $26,000, but actual hospital, surgeon, travel, insurance, and complication costs can differ substantially. Ask the insurer for its written medical policy and ask a bariatric program to explain its required testing and documentation.

Safety and routine questions for a clinician or pharmacist

GLP-1 medicines can cause nausea, vomiting, diarrhea, constipation, and abdominal pain. The FDA labels also include warnings and precautions involving pancreatitis, gallbladder disease, kidney problems related to volume depletion, diabetic retinopathy complications in people with type 2 diabetes, and other concerns. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Wegovy or Zepbound. After bariatric surgery, symptoms such as poor intake, vomiting, fatigue, diarrhea, constipation, or abdominal pain deserve particular attention because they can overlap with medicine effects, nutrition deficiencies, and surgical complications. A person should not assume a symptom is routine medication adjustment without contacting the appropriate care team. The labels state that GLP-1 medicines delay stomach emptying. People taking Zepbound should tell healthcare professionals before planned surgery or procedures requiring general anesthesia or deep sedation because rare aspiration reports have occurred in people taking GLP-1 medicines. The label does not establish a universal stop-or-continue rule; the prescribing and procedural teams should coordinate that decision. Bring a concise record to the appointment: current and prior weights, waist trend if you track it, surgery type and date, lowest post-surgery weight, medicine list, supplements, recent laboratory results, insurance letters, and symptoms. Lina is a GLP-1 companion app for people using Wegovy, Mounjaro, Ozempic, Zepbound, Saxenda, and related medications. It helps users track doses, side effects, meals, weight, protein, hydration, and habits in one place. It is a wellness tracking companion, not a medical device or a substitute for medical advice.